JS203 combined with lenalidomide

Phase 2

JS203 combined with lenalidomide is one of 10 therapeutic programs targeting B-cell non-Hodgkins lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell Non-Hodgkins LymphomaActive, not recruiting

B-Cell Non-Hodgkins LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in B-Cell Non-Hodgkins Lymphoma

#DrugCompanyPhaseTrials

Treanda

AAzurity Pharmaceuticals

Approved

—2

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Imbruvica

Brukinsa

Velcade

SShilpa Grover, MD, MPH

Epkinly

Zynlonta

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Preclinical

—9

JS203 combined with lenalidomide

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

1 10

Bendamustine Hydrochloride

SSymBio Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

B-Cell Non-Hodgkins Lymphoma

NCT07081022

Clinical

Trials by Indication[1]

B-cell non-Hodgkins lymphoma1 trial

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07081022·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JS203 combined with lenalidomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for JS203 combined with lenalidomide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Junshi Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SShanghai Junshi Bioscience Co., Ltd.

JS203 combined with lenalidomide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

B-cell non-Hodgkins lymphoma1 trial

References

Drug Info

Quick Facts

Related News